Skip to main content
PYXS
NASDAQ Life Sciences

Pyxis Oncology Q2 2026: Cash Runway to Q2 2027, Going Concern Remains

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.315
Mkt Cap
$201.47M
52W Low
$1
52W High
$5.55
52W Position info
232% above low
Off High info
40% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

PYXS has more than doubled off its 52-week low of $1.

Summary

Pyxis Oncology's Q2 2026 10-Q shows a $25.3M quarterly loss, a cash runway into Q2 2027 after a $50M private placement, and a continued going concern warning.


Key Events · Earnings and Guidance · PYXS

  • Q2 Net Loss Widens

    Net loss of $25.3 million for Q2 2026, up from $18.4 million in Q2 2025. Six-month loss of $48.6 million versus $39.5 million a year ago.

  • Cash Runway to Q2 2027

    Cash, equivalents, and marketable securities of $33.0 million at June 30, 2026, plus $50 million gross from the July 2 private placement, funds operations into Q2 2027.

  • Going Concern Warning Reiterated

    Management states substantial doubt about continuing as a going concern for 12 months from issuance, even after the private placement.

  • Private Placement Terms

    19,600,153 shares at $2.551 per share, plus warrants for an equal number of shares at $3.289 exercise price. Up to $64 million additional if warrants are fully exercised.


Analysis · PYXS · Life Sciences

A net loss of $25.3 million for the second quarter pushed the six-month deficit to $48.6 million. The company extended its cash runway into Q2 2027 following a $50 million private placement, but management still states substantial doubt about its ability to continue as a going concern beyond 12 months. The filing also reveals the termination of the Biosion license for PYX-106 and a separation agreement with the former CEO.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PYXS was trading at $3.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.5M. The 52-week trading range was $1.00 to $5.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PYXS - Latest Insights

PYXS
Nov 19, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.80 info
Change: +$0.300 (+20%) info
Market Cap: $215.294M info
PYXS
Nov 18, 2026, 6:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.80 info
Change: +$0.340 (+23%) info
Market Cap: $215.294M info
PYXS
Nov 13, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.80 info
Change: +$0.220 (+14%) info
Market Cap: $215.294M info
PYXS
Nov 05, 2026, 7:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $1.80 info
Change: +$0.150 (+9%) info
Market Cap: $215.294M info
PYXS
Nov 05, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.80 info
Change: +$0.150 (+9%) info
Market Cap: $215.294M info